TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy

• Published in: Gan to kagaku ryoho Vol. 29; no. 10; p. 1823
• Main Authors: Nakamura, Masato, Maruyama, Kentarou, Furukawa, Junkou, Maruyama, Naomi, Tanaka, Junnichi, Katsumoto, Yoshihiro, Yokouchi, Hideoki, Nakaguchi, Kazunori, Sue, Fumiaki, Yoshihara, Wataru
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.10.2002
• Subjects: Aged; Anemia - chemically induced; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cisplatin - administration & dosage; Cisplatin - adverse effects; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia - chemically induced; Lymphatic Metastasis; Male; Middle Aged; Nausea - chemically induced; Neoadjuvant Therapy; Oxonic Acid - administration & dosage; Oxonic Acid - adverse effects; Preoperative Care; Pyridines - administration & dosage; Pyridines - adverse effects; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Tegafur - administration & dosage; Tegafur - adverse effects
• ISSN: 0385-0684

Five patients with inoperable advanced gastric cancer were treated with combination chemotherapy of TS-1 and cisplatin (CDDP). TS-1 of 80-120 mg/body/day was orally administered for 3 weeks followed by 2 drug-free weeks, and 60 mg/m2/day of CDDP was venally administered on Day 8. It was possible to evaluate all 5 patients for response and toxicity. Only low grade toxicities (Grade 1 or 2) of leukocytopenia, neutrocytopenia, anemia, nausea, diarrhea and stomatitis were seen. Four of 5 patients achieved a partial response, for a response rate of 80.0%. Stomach, liver, lymph node and peritoneal tumors responded to TS-1/CDDP. TS-1/CDDP therapy produces a high response in cases of gastric cancer, and it is useful as a neoadjuvant chemotherapy.